Asia

Eisai Co., Ltd. has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai’s antiepileptic drug (AED) perampanel as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older. This NDA is the first to be submitted for perampanel in China.

Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.

With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.

Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.

China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.

Eisai Co., Ltd. announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima/Kisplyx (lenvatinib mesylate, “lenvatinib”, selective inhibitor of receptor tyrosine kinases with a novel binding mode) and Halaven (eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany, from October 19 to 23, 2018.

Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.

Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.

In a monumental new breakthrough, scientists in Japan have created an immature human egg using stem cells that were created from blood cells. While immature human eggs have been successfully created in the lab before, this marks the first time that researchers have been able to do it using human blood.

From 1-4 October, more than 2,500 public health experts from over 120 countries convened in Kuala Lumpur at the 2018 World Cancer Congress (WCC).